Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2007 Nov;99(11):1218–1226.

Associations of race and ethnicity with anemia management among patients initiating renal replacement therapy.

Steven D Weisbord 1, Linda F Fried 1, Maria K Mor 1, Abby L Resnick 1, Paul L Kimmel 1, Paul M Palevsky 1, Michael J Fine 1
PMCID: PMC2574315  PMID: 18020096

Abstract

BACKGROUND: Many patients initiate renal replacement therapy with suboptimal anemia management. The factors contributing to this remain largely unknown. The aim of this study was to assess the associations of race and ethnicity with anemia care prior to the initiation of renal replacement therapy. METHODS: Using data from the medical evidence form filed for patients who initiated renal replacement therapy between 1995-2003, we assessed racial and ethnic differences in pre-end-stage renal disease hematocrit levels, the use of erythropoiesis stimulation agents (ESAs), the proportion of patients with hematocrit levels > or = 33% and the proportion of patients with hematocrit levels < 33% that did not receive ESA. We also examined secular trends in racial and ethnic differences in these parameters. RESULTS: In multivariable analyses, non-Hispanic blacks had lower hematocrit levels (delta hematocrit = -0.97%, 95% CI: -1.00-0.94%), and were less likely to receive ESA (OR = 0.82, 95% CI: 0.81-0.84), to initiate renal replacement therapy with hematocrit > or = 33% (OR = 0.78, 95% CI: 0.77-0.79) or to receive ESA if the hematocrit was < 33% (OR = 0.79, 95% CI: 0.77-0.80) than non-Hispanic whites. White Hispanics also had lower hematocrit levels (delta hematocrit = -0.42%, 95% CI:-0.47% to -0.37%), and were less likely to receive ESA (OR = 0.86, 95% CI: 0.85-0.88), to have hematocrit levels > or = 33% (OR = 0.91, 95% CI: 0.89-0.93) or to receive ESA if the hematocrit was < 33% (OR = 0.85, 95% CI: 0.83-0.87) than non-Hispanic whites. These disparities persisted over the eight-year study period. CONCLUSIONS: African-American race and Hispanic ethnicity are associated with suboptimal pre-end-stage renal disease anemia management. Efforts to improve anemia care should incorporate targeted interventions to decrease these disparities.

Full text

PDF
1218

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beusterien K. M., Nissenson A. R., Port F. K., Kelly M., Steinwald B., Ware J. E., Jr The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996 May;7(5):763–773. doi: 10.1681/ASN.V75763. [DOI] [PubMed] [Google Scholar]
  2. Boulware L. Ebony, Cooper Lisa A., Ratner Lloyd E., LaVeist Thomas A., Powe Neil R. Race and trust in the health care system. Public Health Rep. 2003 Jul-Aug;118(4):358–365. doi: 10.1016/S0033-3549(04)50262-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cotter D. J., Thamer M., Kimmel P. L., Sadler J. H. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996. Kidney Int. 1998 Dec;54(6):2129–2139. doi: 10.1046/j.1523-1755.1998.00187.x. [DOI] [PubMed] [Google Scholar]
  4. Drüeke Tilman B., Locatelli Francesco, Clyne Naomi, Eckardt Kai-Uwe, Macdougall Iain C., Tsakiris Dimitrios, Burger Hans-Ulrich, Scherhag Armin, CREATE Investigators Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006 Nov 16;355(20):2071–2084. doi: 10.1056/NEJMoa062276. [DOI] [PubMed] [Google Scholar]
  5. Epstein A. M., Ayanian J. Z., Keogh J. H., Noonan S. J., Armistead N., Cleary P. D., Weissman J. S., David-Kasdan J. A., Carlson D., Fuller J. Racial disparities in access to renal transplantation--clinically appropriate or due to underuse or overuse? N Engl J Med. 2000 Nov 23;343(21):1537-44, 2 p preceding 1537. doi: 10.1056/NEJM200011233432106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Escarce J. J., Epstein K. R., Colby D. C., Schwartz J. S. Racial differences in the elderly's use of medical procedures and diagnostic tests. Am J Public Health. 1993 Jul;83(7):948–954. doi: 10.2105/ajph.83.7.948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Evans R. W., Rader B., Manninen D. L. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA. 1990 Feb 9;263(6):825–830. [PubMed] [Google Scholar]
  8. Kent S. Interpretations of differences in population hemoglobin means: a critical review of the literature. Ethn Dis. 1997 Spring-Summer;7(2):79–90. [PubMed] [Google Scholar]
  9. Kimmel P. L., Greer J. W., Milam R. A., Thamer M. Trends in erythropoietin therapy in the U.S. dialysis population: 1995 to 1998. Semin Nephrol. 2000 Jul;20(4):335–344. [PubMed] [Google Scholar]
  10. Lefebvre Patrick, Duh Mei Sheng, Buteau Sharon, Bookhart Brahim, Mody Samir H. Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease. J Am Soc Nephrol. 2006 Nov 2;17(12):3497–3502. doi: 10.1681/ASN.2006030289. [DOI] [PubMed] [Google Scholar]
  11. Levin A., Thompson C. R., Ethier J., Carlisle E. J., Tobe S., Mendelssohn D., Burgess E., Jindal K., Barrett B., Singer J. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999 Jul;34(1):125–134. doi: 10.1016/s0272-6386(99)70118-6. [DOI] [PubMed] [Google Scholar]
  12. McClellan W. M., Jurkovitz C., Abramson J. The epidemiology and control of anaemia among pre-ESRD patients with chronic kidney disease. Eur J Clin Invest. 2005 Dec;35 (Suppl 3):58–65. doi: 10.1111/j.1365-2362.2005.01532.x. [DOI] [PubMed] [Google Scholar]
  13. Moreno F., Sanz-Guajardo D., López-Gómez J. M., Jofre R., Valderrábano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol. 2000 Feb;11(2):335–342. doi: 10.1681/ASN.V112335. [DOI] [PubMed] [Google Scholar]
  14. Nissenson A. R. Epoetin and cognitive function. Am J Kidney Dis. 1992 Jul;20(1 Suppl 1):21–24. [PubMed] [Google Scholar]
  15. Obrador G. T., Ruthazer R., Arora P., Kausz A. T., Pereira B. J. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol. 1999 Aug;10(8):1793–1800. doi: 10.1681/ASN.V1081793. [DOI] [PubMed] [Google Scholar]
  16. Owen W. F., Jr, Chertow G. M., Lazarus J. M., Lowrie E. G. Dose of hemodialysis and survival: differences by race and sex. JAMA. 1998 Nov 25;280(20):1764–1768. doi: 10.1001/jama.280.20.1764. [DOI] [PubMed] [Google Scholar]
  17. Ritz Eberhard, Laville Maurice, Bilous Rudy W., O'Donoghue Donal, Scherhag Armin, Burger Ulrich, de Alvaro Fernando, Anemia Correction in Diabetes Study Investigators Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis. 2007 Feb;49(2):194–207. doi: 10.1053/j.ajkd.2006.11.032. [DOI] [PubMed] [Google Scholar]
  18. Ronsaville D. S., Hakim R. B. Well child care in the United States: racial differences in compliance with guidelines. Am J Public Health. 2000 Sep;90(9):1436–1443. doi: 10.2105/ajph.90.9.1436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sarnak Mark J., Tighiouart Hocine, Manjunath Guruprasad, MacLeod Bonnie, Griffith John, Salem Deeb, Levey Andrew S. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol. 2002 Jul 3;40(1):27–33. doi: 10.1016/s0735-1097(02)01938-1. [DOI] [PubMed] [Google Scholar]
  20. Shenolikar Rahul A., Balkrishnan Rajesh, Camacho Fabian T., Whitmire J. Timothy, Anderson Roger T. Race and medication adherence in Medicaid enrollees with type-2 diabetes. J Natl Med Assoc. 2006 Jul;98(7):1071–1077. [PMC free article] [PubMed] [Google Scholar]
  21. Singh Ajay K., Szczech Lynda, Tang Kezhen L., Barnhart Huiman, Sapp Shelly, Wolfson Marsha, Reddan Donal, CHOIR Investigators Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16;355(20):2085–2098. doi: 10.1056/NEJMoa065485. [DOI] [PubMed] [Google Scholar]
  22. Yancy Clyde W. Heart failure in African Americans: unique etiology and pharmacologic treatment responses. J Natl Med Assoc. 2003 Jan;95(1):1-9, quiz 10-2. [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES